Table 2.

Studies on PET compared to surgery followed by endocrine therapy

Ref., author	Number of patients	Therapy	Follow-up	Outcome	ER status evaluated
[18, 19] Mustacchi et al.	474	Mastectomy plus tamoxifen 20 mg daily or tamoxifen 20 mg daily alone Both groups received a 160-mg loading dose on day 1	13 years	OS HR (95% CI) 0.98 (0.77–1.25) PFS HR (95% CI) 0.65 (0.53–0.81)	Yes
[20] Fennessy et al.	455	Mastectomy plus tamoxifen 40 mg or tamoxifen 40 mg daily	Median of 12.7 years	OS HR (95% CI) 0.78 (0.63–0.96) PFS not calculated	Unknown
[21] Johnston et al.	153	Mastectomy plus tamoxifen 20 mg daily or tamoxifen 20 mg daily	Median of 6.5 years	OS at 5 years: P = 0.206 OS at 10 years: P = 0.802 PFS not calculated	Yes
[17] Wilsher et al.	147	Mastectomy plus tamoxifen 20 mg daily or tamoxifen 20 mg daily	Median of 3 years	OS HR (95% CI) 0.80 (0.73–2.32) PFS not calculated	Yes

ER oestrogen receptor, OS overall survival, HR hazard ratio, CI confidence interval, PFS progression-free survival